company background image
HEPA logo

Hepion Pharmaceuticals NasdaqCM:HEPA Stock Report

Last Price

US$2.49

Market Cap

US$10.8m

7D

7.3%

1Y

-83.2%

Updated

28 Mar, 2024

Data

Company Financials +

Hepion Pharmaceuticals, Inc.

NasdaqCM:HEPA Stock Report

Market Cap: US$10.8m

HEPA Stock Overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

HEPA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Hepion Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hepion Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.49
52 Week HighUS$20.66
52 Week LowUS$1.49
Beta1.56
1 Month Change4.18%
3 Month Change-23.15%
1 Year Change-83.21%
3 Year Change-93.74%
5 Year Change-99.32%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

Shareholder Returns

HEPAUS PharmaceuticalsUS Market
7D7.3%2.2%0.2%
1Y-83.2%25.5%28.1%

Return vs Industry: HEPA underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: HEPA underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is HEPA's price volatile compared to industry and market?
HEPA volatility
HEPA Average Weekly Movement17.5%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: HEPA's share price has been volatile over the past 3 months.

Volatility Over Time: HEPA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201325John Cavanhttps://www.hepionpharma.com

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.

Hepion Pharmaceuticals, Inc. Fundamentals Summary

How do Hepion Pharmaceuticals's earnings and revenue compare to its market cap?
HEPA fundamental statistics
Market capUS$10.84m
Earnings (TTM)-US$47.82m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HEPA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$47.82m
Earnings-US$47.82m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-11.02
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did HEPA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.